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Background
Trastuzumab (Herceptin), an antagonist to the human
epidermal growth factor 2 (HER2) receptor, significantly
decreases the rates of breast cancer recurrence and mortal-
ity by 50%. Despite therapeutic benefits, the risk of cardi-
otoxicity with Trastuzumab ranges from 10–15% when
administered in combination with anthracyline therapy.
Although serial multiple gated acquisition scans are
widely used to monitor cardiac dysfunction in breast can-
cer patients, cardiac MRI (CMR) is becoming the gold
standard for the non-invasive assessment of left ventricu-
lar (LV) systolic dysfunction in dilated cardiomyopathies.
Objective
To describe the utility of CMR in the assessment of Trastu-
zumab induced cardiomyopathy.
Methods
Between 2005–2006 inclusive, 160 breast cancer patients
who received Trastuzamab in addition to anthracyline
based adjuvant therapy were identified at a tertiary care
oncology centre. Of the total population, 20 patients were
identified with Trastuzumab induced cardiomyopathy
based on LV ejection fraction (EF) less than 40% on either
serial MUGA or echocardiography. Cardiac MRI was per-
formed on all 20 patients using a 1.5 T scanner to deter-
mine LV volumes and systolic function. Delayed-
enhancement inversion recovery CMR (DE-CMR) was
performed after 10 minutes of 0.2 mmol/kg injection of
Gadolinium in all patients to assess scar formation.
Results
The total population included 20 patients (mean age 42 ±
12 years, range 30 to 64 years). At the time of diagnosis of
Trastuzumab induced cardiomyopathy, the LV cavities
were dilated with moderate to severe global LV systolic
dysfunction on CMR. The mean LVEF was 29 ± 4%. Sub-
epicardial linear delayed enhancement was present in the
lateral portion of the left ventricles in all 20 patients sug-
gesting the presence of Trastuzumab induced myocarditis
(Figure 1).
Conclusion
DE-CMR is a novel way of detecting early changes in the
myocardium due to Trastuzumab induced cardiotoxicity.
Future studies are required to validate identification of
positive delayed enhancement using CMR as a subclinical
marker for future LV dysfunction in this select population.
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